Norristown, PA, United States
Norristown, PA, United States

Time filter

Source Type

Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-08-14

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-12-09

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-03-19

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-03-05

Compositions and methods for decreasing phosphorus, decreasing cFGF23, or increasing iFGF23 in a subject. Such compositions and methods can be useful for treatment of conditions, disorders, or diseases associated with phosphorus or FGF23 disregulation.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-03-05

Admixing carbon dioxide with an aqueous ketorolac solution is useful for increasing the stability of ketorolac in the carbon dioxide-admixed solution.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2015-01-06

Disclosed herein are devices and processes for preparing a vial for an intranasal administration of a medicament where the vial comprises reduced oxygen content.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2015-04-10

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2014-10-09

Pharmaceutical formulations of bendamustine for pharmaceutical use and methods related thereto. The formulations and methods described herein utilize a polar aprotic solvent, or mixture thereof, that can be used to produce lyophilized bendamustine.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2016-10-19

The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof.


Patent
Luitpold Pharmaceuticals Inc. | Date: 2013-07-26

Methods for predicting responsiveness of a subject to iron therapy and treatment methods related thereto. Such methods can be useful with respect to conditions, disorders, or diseases associated with iron deficiency anemia.

Loading Luitpold Pharmaceuticals Inc. collaborators
Loading Luitpold Pharmaceuticals Inc. collaborators